Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer's TrialGlobeNewsWire • 12/14/22
Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/12/22
Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022GlobeNewsWire • 12/02/22
Anavex Catapults On Alzheimer's Results — But Math Question Clouds The DataInvestors Business Daily • 12/02/22
ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer's DiseaseGlobeNewsWire • 12/02/22
Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business UpdateGlobeNewsWire • 11/28/22
Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022GlobeNewsWire • 11/23/22
Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX®2-73 (blarcamesine) for the Treatment of Fragile X SyndromeGlobeNewsWire • 11/07/22
Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2b/3 Data of Oral ANAVEX®2-73 (blarcamesine) for Early Alzheimer's Disease at the Upcoming Clinical Trials on Alzheimer's Disease (CTAD) Congress 2022GlobeNewsWire • 10/17/22
Anavex Life Sciences Announces Issuance of U.S. Patent Covering ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders TherapyGlobeNewsWire • 09/21/22
Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease DementiaSeeking Alpha • 09/19/22
Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's DiseaseSeeking Alpha • 09/07/22
Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation to Compensate for Early Alzheimer's DiseaseGlobeNewsWire • 08/23/22